ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
This field is for validation purposes and should be left unchanged.

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
This field is for validation purposes and should be left unchanged.
go to the article

go back to the homepage

  • BIOCOM CARD
  • Newsletter
  • Advertising
  • Job Market
  • Shop
European Biotechnology Magazine
biocom_logo
  • Latest news
  • Background
  • Opinion
  • The Mag
    • Issues
    • Special
    • Subscribe
  • Euro Biotech Guide
  • Market Place
    • Products
    • Sponsored Publications
    • Advertise
  • Associations
  • Service
    • Job Market
    • Newsletter
    • Contact Us
    • Editorial Team
  • Events
  • Search
  • Menu Menu

ADVERTISEMENT

LATEST NEWS

Swiss biotech continues to do well

Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new … more ➔

placeholder

Recipharm in €68m Mitim takeover

Recipharm remains on track for growth. The Swedish CDMO is acquiring Italian injectable beta lactam expert Mitim Srl. The takeover is worth €68.4m. more ➔

Page 200 of 200«‹198199200

BACKGROUND

Indivumed GmbH

Unlocking the treasure trove

From Emissions to Solutions: “Best CO2 Utilisatio...

Vetter Prioritizes Continuity and Action in its Sus...

ADVERTISEMENT

MAGAZINE

1 / 4

This issue focuses on the art of upscaling industrial biotechnology in Europe, the impact of the Trump factor on the life sciences and the European Commission's new billion-euro fund for emerging … more ➔

2 / 4

This issue offers insights into Europe's fight for green solutions for a bioeconomy, antimicrobial resistance and how Europe is preparing for the next pandemic. more ➔

3 / 4

Since the first antibody drug was approved back in 1986, monoclonal antibodies have emerged as the dominant class in the global US$417bn market for biologics. At the end of 2023, sales stood at more … more ➔

4 / 4

The first half of 2024 is history, and experts are divided on whether the financing nadir has been reached or even passed. There are very different figures for different types of treatments under … more ➔

❮❯

SPONSORED PUBLICATION

1 / 2
New England Biolabs

The Bridge to your success

Customized Enzymes and Reagents from New England Biolabs more ➔

2 / 2
GettyImages
The Altascientist

Discover the Dynamic Landscape of GLP-1 Drug Development

Explore the evolving world of GLP-1 receptor agonists in Issue 42 of The Altascientist, featuring insights on their expanding applications, early-phase development, and real-world case studies. more ➔

newsletter_link
© BIOCOM Interrelations GmbH
  • LinkedIn
  • Instagram
  • Contact
  • Imprint
  • Privacy policy
Scroll to top